StratDeck

Two stocks in Healthcare

Genmab A/S vs Novartis: profit, growth, debt and price compared

Genmab A/S is stronger on 4 of 6 figures: sales growth, debt, analysts' view and price trend. Novartis is stronger on 2: profit margin and price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore Genmab A/S' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Genmab A/S and Novartis side by side
Genmab A/SGMAB.CONovartisNOVN.SW
Net margin17.0%Stronger: 17.5%
Revenue growth, past yearStronger: +16.10%+4.70%
Debt to equityStronger: 82.1%128.6%
Forward P/E29.9×Stronger: 15.9×
Dividend yield—2.78%
AnalystsStronger: Strong buy · 13Hold · 22
From its 200-day averageStronger: +54.9%+9.2%

Share price over the past year

  • Genmab A/S+79.0%
  • Novartis+25.9%

14 Nov 202518 Nov 2026

Genmab A/S or Novartis: which is stronger?

  • NOVN.SW

    Which is more profitable?

    Novartis keeps more of each sale as profit: 17.5% against 17.0%.

  • GMAB.CO

    Which is growing its sales faster?

    Genmab A/S is growing its sales faster: +16.10% over the past year, against +4.70%.

  • GMAB.CO

    Which has borrowed less?

    Genmab A/S has borrowed less: its debt is 82.1% of what its shareholders own, against 128.6% for Novartis.

  • NOVN.SW

    Which costs less for the profit it is expected to make?

    Novartis costs less for the profit it is expected to make: 15.9× its forward earnings, against 29.9×.

  • Which pays more in dividends?

    Novartis pays 2.78% a year in dividends for what a share costs, where Genmab A/S pays none.

  • GMAB.CO

    Which do analysts rate higher?

    Analysts are warmer on Genmab A/S: Strong buy, against Hold for Novartis.

  • GMAB.CO

    Which is in the stronger price trend?

    Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 9.2% above.

What each company does

GMAB.COGenmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Reports results on 16 February 2027

NOVN.SWNovartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.